Add-on treatment with the SGLT1 and 2 inhibitor sotagliflozin may reduce cardiovascular risk among patients with type 2 diabetes and chronic kidney disease, suggest findings from the SCORED trial published in The New England Journal of Medicine.
Starting sotagliflozin in people with type 2 diabetes during or shortly after hospitalization for heart failure significantly reduces their risk for further cardiovascular events over the following months, show the results of the SOLOIST-WHF trial.
Geographic remoteness is strongly associated with a reduced likelihood of being prescribed the most recent classes of glucose-lowering medications, find Australian researchers.
The selective mineralocorticoid receptor antagonist finerenone significantly reduces the risk for progression of chronic kidney disease and for cardiovascular events in people with type 2 diabetes, show the FIDELIO-DKD findings.
Secondary analysis of the VERTIS CV trial supports a significant protective effect of ertugliflozin on risk for heart failure in people with type 2 diabetes, despite the overall neutral outcome of the trial.
Miles Fisher comments on the findings from the EMPEROR-Reduced trial, which demonstrated cardioprotective effects of empagliflozin irrespective of diabetes in patients with heart failure, and discusses whether SGLT2 inhibitors should be incorporated into heart failure treatment guidelines (5:08).
DAPA-CKD lead investigator Hiddo Heerspink discusses the positive outcomes of dapagliflozin treatment in people with kidney disease both with and without type 2 diabetes (8:13).
Lead investigator Milton Packer compares the EMPEROR-Reduced results with those of the DAPA-HF trial, and talks about how SGLT2 inhibitors will impact the treatment of heart failure (6:27).
The pilot MIDDAS study suggests that a 2-day per week very-low-calorie diet could be a viable alternative to a continuous diet for people with type 2 diabetes who struggle with this approach.
Juliana Chan outlines current knowledge about the relationship between diabetes and COVID-19, discussing risk factors for poor outcomes in people with both conditions and the need for collaborative efforts to improve patient care (7:09).
The results of the phase 2 LIBERATES trial suggest that flash glucose monitoring could reduce the time people with type 2 diabetes spend in hypoglycemia in the period following an acute coronary syndrome.
A small randomized crossover trial indicates that treatment with empagliflozin in people with type 2 diabetes and heart failure already using a loop diuretic results in increased urine output without sodium loss.
A meta-analysis of the DAPA-HF and EMPEROR-Reduced trials supports use of SGLT2 inhibitors in people with heart failure with or without diabetes, and suggests a positive effect on mortality endpoints.
The EMPEROR-Reduced investigators have revealed that empagliflozin provides significant protection against cardiovascular death and heart failure in patients with heart failure and reduced ejection fraction, with or without diabetes.
The primary findings of the DAPA-CKD trial show that dapagliflozin significantly slows decline in kidney function in patients with chronic kidney disease irrespective of whether they have type 2 diabetes.
Among people with obesity and type 2 diabetes, substantial weight loss is associated with similar metabolic benefits irrespective of whether it is achieved through gastric bypass surgery or diet, suggests research published in The New England Journal of Medicine.
Both type 1 and type 2 diabetes are independently associated with an increased risk for death among hospitalized patients with COVID-19, and a number of factors including poor glycemic control and BMI may predict mortality risk, suggest findings from two studies published in The Lancet Diabetes & Endocrinology.
Researchers studying the MESA cohort have proposed BMI cutoffs at which people from ethnic minorities should be screened for type 2 diabetes, all of which are lower than their proposed cutoff for White people.
Severe hypoglycemia in people with type 2 diabetes is associated with later mortality from a wide range of causes, including those for which there is no obvious underlying mechanism, say researchers.
A large study of data from people with type 2 diabetes in general practice reveals that non-cardiovascular comorbidities such as osteoarthritis and depression are common, and significantly more so than in people without diabetes.
Phase 3 trials of tirzepatide in type 2 diabetes and obesity
Tirzepatide (formerly known as LY3298176) is a novel glucose-lowering medication that stimulates the receptors for both glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1.
DiRECT trial dietitian Alison Barnes discusses the challenges and triumphs of using a very-low-calorie, total-meal-replacement diet to help people with type 2 diabetes achieve weight loss and maintenance (25:34).
Diagnosis and management of prediabetes: a consensus of GCC countries
Guidance based on outcomes of an advisory board of diabetes experts, for healthcare professionals addressing the diagnosis and treatment of prediabetes.
This interactive roadmap is intended for healthcare professionals practicing in Saudi Arabia, Kuwait, the United Arab Emirates, Qatar, Bahrain, and Oman.
Funding for this roadmap was provided by Merck Serono Middle East FZ-LLC
These slide sets summarize the results of clinical studies and randomized controlled trials investigating the use of flash glucose-sensing technology in patients with diabetes.
Funded by an educational grant from Abbott Diabetes Care
An updated collection of articles focusing on the mechanism of action and clinical use of sodium-glucose cotransporter-2 inhibitors in patients with diabetes.
The authors report on ameta-analysis of real-world observational studies on the impact of flash continuous glucose monitoring on glycemic control as measured by HbA1c.
A convenient single access point, providing diabetes professionals with links to a comprehensive set of clinical practice guidelines from a wide range of relevant organizations.
Practical information, guidance, and helpful resources for diabetes healthcare providers. Comprised of practical approaches, case studies, and more.
Themed collections
Compendia of selected, recently published, free full-text journal and book content from Springer Nature and other publishers on a particular topic within diabetes management, as recommended by our Editorial Board.
Educational programs building upon the most current research and professional practice recommendations, with the aim of enabling more efficient diagnosis, optimizing treatment, and improving patient outcomes.
